Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549636 | 0.83 | HPGD (0.52) | HSD17B10MAPTDRD3OPRK1HSP90AA1 | |
| SCHEMBL16415859 | 0.72 | MAPT (0.50) | HSD17B10POLBMAPTALDH1A1LMNA | |
| SCHEMBL17549673 | 0.72 | HSD17B10 (0.55) | HSD17B10DRD3OPRD1HSP90AA1ALDH1A1 | |
| SCHEMBL27811710 | 0.71 | HSD17B10 (0.73) | HSD17B10MAPTDRD3HSP90AA1ALDH1A1 | |
| SCHEMBL17549634 | 0.70 | HSD17B10 (0.52) | HSD17B10MAPTHSP90AA1ALDH1A1LMNA | |
| SCHEMBL104400 | 0.70 | KMT2A (0.78) | POLBALDH1A1LMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6048626 | 0.70 | HSD17B10 (0.71) | HSD17B10MAPTDRD3HSP90AA1ALDH1A1 | |
| SCHEMBL14774780 | 0.70 | MAPT (0.48) | HSD17B10MAPTALDH1A1LMNA | |
| SCHEMBL21834949 | 0.69 | USP5 (0.59) | POLBUSP5ALDH1A1LMNAMEN1 | |
| SCHEMBL15599303 | 0.69 | HSD17B10 (1.00) | HSD17B10POLBMAPTDRD3HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | HSD17B10 3806/4885POLB 985/4885MAPT 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.